Altimmune, Inc. · NASDAQ:ALT
Altimmune — Pharmathene — Rodman & Renshaw Annual Global Investment Conference 2013
23 slides from Altimmune's conference presentation, Sep 9, 2013
Slide 1: Rodman & Renshaw Annual Global Investment Conference September 9, 2013
Rodman & Renshaw Annual Global Investment Conference September 9, 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for the historical information presented herein, matters discussed may constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results t
Slide 3: Important Additional Information About the Merger
Important Additional Information About the Merger This communication is being made in respect of the proposed merger involving Theraclone Sciences, Inc. (“Theraclone”) and PharmAthene. On August 1, 2013, PharmAthene filed with the SEC a current report on Form 8 - K, which includes the merger agreeme
Slide 4: No Offer or Solicitation
No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction in connection w
Slide 5: PharmAthene / Theraclone
PharmAthene / Theraclone PharmAthene, Inc., (NYSE MKT: PIP) a leading biodefense company, and Theraclone Sciences, Inc., a monoclonal antibody discovery and development company, announced an intention to merge to form a commercially - focused biologics company with extensive vaccines and therapeutic
Slide 6: Combined Company – Investment Opportunity
6 Combined Company – Investment Opportunity Compelling transaction with complementary capabilities to realize synergies and accelerate value Premier biologics company with vaccine and antibody expertise and a focus on infectious diseases and oncology Four clinical programs and multiple partnered pre
Slide 7: Biologics Company with Significant Growth Potential
7 Biologics Company with Significant Growth Potential Non - dilutive funding to drive near - term growth Product development milestones and deals to drive long - term growth DEVELOP SIGNIFICANT COMMERCIAL PRODUCTS DEVELOP GOVERNMENT MARKETS LEVERAGE PROPRIETARY I - STAR™ PLATFORM • Flu Antibody (TCN
Slide 8: New Market Opportunity – Antibody Therapeutics
8 New Market Opportunity – Antibody Therapeutics • Fastest growing segment of the biopharmaceutical industry • Top 5 antibody products have sales of $5 billion each annually * • 5 of the top 10 selling drugs are monoclonal antibodies * • Clear regulatory pathway to approval • Proven manufacturing pr
Slide 9: Diversified Clinical Pipeline Targeting Large Market Opportunities
PRODUCT INDICATION PRE - CLINICAL PHASE I PHASE IIa PHASE IIb MARKET OPPORTUNITIES MARKET POTENTIAL SparVax ® Recombinant protective antigen (rPA) anthrax vaccine Anthrax Infection >$1B USG Stockpile Opportunity* Flu mAb TCN - 032 Influenza A Therapeutic Severe Seasonal and Pandemic Flu ~$600MM Est.
Slide 10: I-STAR Validating Partnerships
10 I - STAR TM Validating Partnerships January 2011 I - STAR™ collaboration to discover antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. Pfizer has Worldwide licensing rights. February 2008 IAVI collaboration to discover HIV - neutralizing antibodies M
Slide 11: Flu Antibody: TCN-032
11 Flu Antibody: TCN - 032 • IgG mAb that binds to a novel, highly - conserved universal epitope – Influenza A (H1N1; H5N1; H7N9) • Annually, 200,000 U.S. patients are hospitalized; 36,000 die from serious influenza infections* • Government stockpile market offers significant upside potential • Phas
Slide 12: Cytomegalovirus (CMV) Antibody: TCN-202
12 Cytomegalovirus (CMV) Antibody: TCN - 202 • Recognizes broadly conserved epitope on CMV • Neutralizes CMV viral infection in many cell types – Epithelia, endothelial, fibroblasts, etc. • ~1,000x more potent than plasma - derived CMV - IGIV (preclinical studies)* • Phase 1 completed; favorable saf
Slide 13: SparVax Next Generation Anthrax Vaccine
13 SparVax ® Next Generation Anthrax Vaccine • Highly purified recombinant p rotective antigen – Modern E. coli - based production • 770 individuals in Phase I and Phase II clinical trials • Pre - and post - exposure protection • Enhanced convenience and cost - effectiveness (PEP regimen) – 3 dose I
Slide 14: Valortim Anthrax Anti-Toxin
14 Valortim ® Anthrax Anti - Toxin • Dept. of Homeland Security Material Threat Assessment: 200,000 treatments • HHS procurement program to fulfill requirement Fully human monoclonal antibody (mAb) • Novel mechanism of action similar to natural immune response • Effective Pre - and Post - exposure •
Slide 15: Nerve Agent Bioscavenger rBChE
15 Nerve Agent Bioscavenger rBChE Nerve Agent Bioscavenger to Address Chemical Threats • Prevents physiological damage from chemical nerve agents • Robust advanced expression system (AES) technology platform • $5.7MM in DoD funding • Cell culture - based manufacturing • Scalable manufacturing proces
Slide 16: I-STAR Generating Highly-Specific Human Antibodies
16 I - STAR ™ Generating Highly - Specific Human Antibodies for Significant Unmet Medical Needs Selected donor population convalescent/vaccinated subjects = protective Abs Superior B - cell activation Deep sequencing of all hit wells Rapid screen for binding and function IgG+ Memory B - cells “Archi
Slide 17: Significant Near-Term Revenue Opportunity: Arestvyr
17 Significant Near - Term Revenue Opportunity Arestvyr™ (SIGA Technologies) Oral Smallpox Antiviral Up to ~$2.8B* NOTE: The above is based solely on information from the following public sources: SIGA press releases and other public statem ent s, research analyst reports, SEC filings • $2.8B* U.S.
Slide 18: Significant Revenue Opportunity: Arestvyr
18 Significant Revenue Opportunity Arestvyr™ (SIGA Technologies) Oral Smallpox Antiviral • Breach of contract lawsuit filed by PharmAthene in December 2006 • Trial court awarded PharmAthene 50% of net profits on WW sales of Arestvyr™ for 10 years once SIGA retains the first $40MM in profit • Decisio
Slide 19: Combined Company Executive Team
19 Combined Company Executive Team Clifford J. Stocks Chief Executive Officer Calistoga Pharmaceuticals, Inc., ICOS Corporation Francesca Cook SVP, Policy and Government Affairs Guilford Pharmaceuticals Covance Health Econ., U.S. HHS Russ Hawkinson Chief Financial Officer Corixa Corporation Ernst &
Slide 20: Combined Company Board of Directors
20 Combined Company Board of Directors Mitch Sayare, Ph.D. Chairman ImmunoGen XenoGen John M. Gill Tetralogic Pharmaceuticals 3D Pharma, SKB Steve Gillis, Ph.D. Immunex, Corixa, ARCH Venture Partners Wende Hutton Canaan Partners Mayfield Fund, GenPharma International Brian Markison King Pharmaceutic
Slide 21: Near-Term Valuation Catalysts
21 Near - Term Valuation Catalysts Initiate CMV antibody Phase 2a study Q3 13 Present Flu Antibody Phase 2a results Q3 13 Present CMV Antibody Phase 1 results Q3 13 Secure additional USG SparVax ® funding Q4 13 Initiate SparVax ® Phase 2 clinical trial Q4 13 Event* Date *The Milestones listed above
Slide 22: Key Terms of the Transaction
22 Key Terms of the Transaction Proposed Transaction: Tax - free, all stock transaction Pro Forma Ownership: Merger of Equals Next Steps: Proxy Statement / Prospectus / Consent Solicitation Stockholder meeting and vote Name: PharmAthene Public Market: NYSE MKT; symbol “PIP”
Slide 23: Rodman & Renshaw Annual Global Investment Conference September 9, 2013
Rodman & Renshaw Annual Global Investment Conference September 9, 2013
Pharmathene — Rodman & Renshaw Annual Global Investment Conference 2013 on 6ix